HomeCompareONCT vs VICI

ONCT vs VICI: Dividend Comparison 2026

ONCT yields 379.79% · VICI yields 6.57%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ONCT wins by $7845.60M in total portfolio value
10 years
ONCT
ONCT
● Live price
379.79%
Share price
$0.53
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7846.59M
Annual income
$5,169,197,450.71
Full ONCT calculator →
VICI
VICI Properties Inc.
● Live price
6.57%
Share price
$27.12
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$988.8K
Annual income
$623,261.32
Full VICI calculator →

Portfolio growth — ONCT vs VICI

📍 ONCT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodONCTVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ONCT + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ONCT pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ONCT
Annual income on $10K today (after 15% tax)
$32,282.57/yr
After 10yr DRIP, annual income (after tax)
$4,393,817,833.10/yr
VICI
Annual income on $10K today (after 15% tax)
$558.67/yr
After 10yr DRIP, annual income (after tax)
$529,772.12/yr
At 15% tax rate, ONCT beats the other by $4,393,288,060.98/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ONCT + VICI for your $10,000?

ONCT: 50%VICI: 50%
100% VICI50/50100% ONCT
Portfolio after 10yr
$3923.79M
Annual income
$2,584,910,356.01/yr
Blended yield
65.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

ONCT
No analyst data
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+16.5% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ONCT buys
0
VICI buys
0
No recent congressional trades found for ONCT or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricONCTVICI
Forward yield379.79%6.57%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$7846.59M$988.8K
Annual income after 10y$5,169,197,450.71$623,261.32
Total dividends collected$7596.65M$948.4K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: ONCT vs VICI ($10,000, DRIP)

YearONCT PortfolioONCT Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$48,679$37,979.49$11,368$948.43+$37.3KONCT
2$224,874$172,787.13$13,339$1,493.16+$211.5KONCT
3$986,585$745,969.70$16,326$2,426.21+$970.3KONCT
4$4,114,314$3,058,668.09$21,123$4,112.15+$4.09MONCT
5$16,323,283$11,920,966.77$29,379$7,368.23+$16.29MONCT
6$61,667,489$44,201,576.55$44,804$14,191.64+$61.62MONCT
7$222,048,216$156,064,002.73$76,658$29,972.12+$221.97MONCT
8$762,773,776$525,182,185.09$150,894$71,015.81+$762.62MONCT
9$2,502,234,339$1,686,066,398.09$350,814$193,582.47+$2501.88MONCT
10$7,846,588,193$5,169,197,450.71$988,809$623,261.32+$7845.60MONCT

ONCT vs VICI: Complete Analysis 2026

ONCTStock

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.

Full ONCT Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this ONCT vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ONCT vs SCHDONCT vs JEPIONCT vs OONCT vs KOONCT vs MAINONCT vs NNNONCT vs EPRTONCT vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.